Ngl Fine Chem Ltd

Stage 3 · Topping · week 5

As of 16 Oct 2026, Ngl Fine Chem is in Stage 3 — topping, where an uptrend loses steam, in week 5 (since 10 Sep 2026). It closed at ₹2,785, 19.5% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. More about the company

₹2,784.6
-0.77% today
₹1,720 Cr · Small cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is NGLFINE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-19.5%
₹1,278.8 lo₹3,457.8 hi
19.5% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 5
1w13w26w
Week 5 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
10.0%
200 DMA: ₹2,532.5 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.26x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↑ ⇈
Accelerating · MA20 +3.1% vs MA50 -4.2% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+4.1%
3M
-11.1%
6M
+23.9%
YTD
+113.0%
1Y
+88.0%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 26w
S4 32w
S2 32w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 12w → S3 9w → S2 9w → S3 2w → S2 26w → S3 5w → S4 32w → S1 3w → S4 3w → S1 10w → S2 10w → S3 9w → S2 32w → S3 5w current
Total tracked: 168 weeks across 14 stage runs.
Scan Membership
Prop Scan
Latest: 2026-08-14
Pullback Hunter
Latest: 2026-07-20
60 appearances in last 60 days. First seen: 2026-06-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 5 · Vol 0.26x
2026-10-15S3
Wk 5 · Vol 0.11x
2026-10-14S3
Wk 5 · Vol 0.11x
2026-10-13S3
Wk 5 · Vol 0.18x
2026-10-12S3
Wk 5 · Vol 0.26x
2026-10-09S3
Wk 4 · Vol 0.23x
2026-10-08S3
Wk 4 · Vol 0.29x
2026-10-07S3
Wk 4 · Vol 0.78x
2026-10-06S3
Wk 4 · Vol 1.38x
2026-10-05S3
Wk 4 · Vol 0.55x
2026-10-01S3
Wk 3 · Vol 1.18x
2026-09-30S3
Wk 3 · Vol 0.31x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹2,934.3
200 DMA
₹2,532.5
52W High
₹3,457.8
52W Low
₹1,278.8
5D Low
₹2,784.6
Resistance levels (recent highs)
20d High
₹3,134.2
60d High
₹3,457.8
120d High
₹3,457.8
250d High
₹3,457.8
Next resistance
+12.6%
to 20d High
Ask the Market AI about NGLFINEAsk →
P/E (TTM)
47.1
Forward —
Earnings Growth (YoY)
+1539.8%
Revenue +57.2%
ROE
+15.7%
Profit margin +9.6%
Dividend Yield
0.06%
P/B 5.6
About this companyHealth Care· Pharmaceuticals

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.